News
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Novo Nordisk reduces its starter dose prices through telehealth platforms to encourage weaning patients off compounded copycats.
Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...
The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...
2don MSN
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
7h
Dagens.com on MSNThis New Pill Could Replace Wegovy and Ozempic — No Injections RequiredA revolution in weight loss treatment may soon be on the way — and it doesn’t involve a needle. Eli Lilly, the pharmaceutical giant behind some of today’s most powerful diabetes and obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results